香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 本公司董事（「董事」，單獨為「董事」）會（「董事會」）茲通告，於2026年2月5日， 本公司接獲由ZTan Limited（一間由本公司執行董事、董事會主席兼首席策略官譚 錚先生全資擁有的英屬處女群島公司）發出的自願承諾函，內容關於ZTan Limited 已自願承諾就其於本公司股份（「股份」）的直接權益，接受僅以本公司為受益人的 禁售承諾（「禁售承諾」）。禁售承諾的詳情載列如下： | | 截至本公告日期 | | | --- | --- | --- | | 截至本公告日期 | 受禁售承諾規限 | | | 受禁售承諾規限 | 之股份佔本公司 | 受禁售承諾規限 | | 之股份數目 | 股權之概約百 ...

Market Overview - The Hang Seng Index opened lower but managed to close up by 0.14% [1] - The geopolitical situation remains stable, with Iran set to negotiate nuclear issues with the U.S. on February 6 [1] - Gold and silver prices fell significantly, with silver dropping over 14% and gold falling more than 2% to below $4,900 per ounce [1] International Relations - Russian President Putin plans to visit China in the first half of 2026 following a video call with Chinese leaders [2] - U.S. and Chinese leaders had a positive discussion regarding regional issues and economic cooperation, with a planned visit by Trump to China in April [2] - China has requested state-owned enterprises to pause new investment projects in Panama [2] Technology Sector - Despite declines in U.S. tech stocks, some Chinese tech companies like Naxin Micro (02676) reported strong earnings and plan to raise product prices by 10%-25% [3] - Baidu (09888) announced a stock buyback plan of up to $5 billion and plans to introduce a dividend policy by 2026, leading to a nearly 3% increase in its stock price [3] - Xiaomi (01810) repurchased shares worth HKD 146 million, also seeing a nearly 3% rise [3] - Tencent (00700) is expected to maintain double-digit growth in its gaming business by 2026, with advertising revenue projected to grow around 20% [3] Consumer Sector - Kweichow Moutai (600519.SH) has shown strong performance, boosting consumer valuations [4] - Oriental Selection (01797) surged over 10% due to its unique brand and membership model [4] - Pop Mart (09992) reported significant demand for its new products, with resale prices on secondary markets showing substantial premiums [4] Restaurant Sector - Yum China (09987) reported total revenue of $11.797 billion for 2025, a 4% increase year-on-year, with net profit rising by 2% [5] - Haidilao (06862) is seeing positive impacts from the return of its founder, with plans for expansion and new brand growth [5] - Brainstorm Aurora-B (06681) announced a strategic partnership to promote digital health products in Southeast Asia, with a significant stock price increase of over 15% [6] Energy Sector - The U.S. is experiencing a surge in natural gas power generation capacity, with over 29 GW under construction, but many projects may face delays due to a lack of available gas turbines [7] - Companies like Eagle Precision (01286) and Dongfang Electric (01072) are positioned to benefit from this trend, with expectations of increased demand for gas turbine components [7] Aviation Sector - Cirrus Aircraft (02507) launched the new G3 Vision Jet, enhancing its product line and expected to improve profit margins [8] - The new jet model is designed for private and corporate users, featuring significant upgrades in safety and comfort [8] - Cirrus is projected to deliver approximately 800 aircraft in 2025, with new orders expected to reach around 600 units [9]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 公司名稱： 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2026年2月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing demand for mental health solutions in the region [1][4]. Group 1: Partnership Details - The collaboration will focus on establishing a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - The partnership includes applying for national innovation pilot projects, with Silk Road leading the engagement with Malaysian authorities [3]. - Clinical pilot projects will be initiated in selected hospitals, with the company responsible for local adaptation, training, and data collection [3]. Group 2: Market Context - Malaysia faces challenges with an aging population and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a counselor-to-population ratio of 1:52,000, far below the international standard of 1:500 [1]. Group 3: Strategic Importance - This partnership marks the company's official entry into the Malaysian market, expanding its Southeast Asian business network and leveraging its experience in the Chinese market [4]. - Silk Road's extensive local resources and networks will facilitate efficient product entry and market adaptation, enhancing commercial conversion rates [4]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and accelerate the deployment of its products in local medical institutions [4].

Core Viewpoint - The company Brainstorm Cell Therapeutics (06681) has seen a stock increase of over 13% following the announcement of a strategic partnership with Silk Road Technology Co., Ltd. to expand its digital therapy products in Malaysia and Southeast Asia [1] Group 1 - The strategic cooperation agreement aims to localize, promote, and transform research related to cognitive impairment digital therapy products in the Malaysian and Southeast Asian markets [1] - The board believes this partnership marks the company's official entry into the Malaysian market, further expanding its Southeast Asian business network [1] - The collaboration is expected to leverage the company's validated digital therapy experience and technology from the Chinese market to enhance its brand influence and business coverage internationally [1]

Group 1 - The core announcement is that Brainstorm Cell Therapeutics has completed a share placement and a rights offering, raising approximately HKD 500.68 million for various strategic purposes [1] - The share placement involved the issuance of 92 million shares at HKD 5.6 per share to at least six independent third-party subscribers, completed on January 27 [1] - The rights offering, which also involved the issuance of 92 million new shares at the same price, was completed on February 5 [1] Group 2 - Following the transactions, the total number of shares for Brainstorm increased from 1.266278 billion to 1.358278 billion [1] - The ownership percentages of concerted parties, other non-public shareholders, and public shareholders have been adjusted as a result of the share issuance [1] - The net proceeds from the offerings are intended for research and development plans, market development, strategic investments, acquisitions, and to supplement working capital [1]

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology to localize and promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry in the region [1][2]. Group 1: Market Context - Malaysia is facing challenges due to rapid population aging and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a psychological counseling ratio of 1:52,000, far below the international standard of 1:500, indicating a substantial market gap [1]. Group 2: Company Background - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first regulatory-approved digital therapy for cognitive impairment, included in the reimbursement catalog of provincial medical insurance in 30 provinces in China [1]. Group 3: Partnership Details - The partnership includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Technology assisting in local approvals and logistics while the company provides technical and research support [3]. - The collaboration will also involve applying for national innovation pilot projects, conducting clinical trials in selected hospitals, and jointly expanding market reach in Malaysia and other Southeast Asian countries like Indonesia, Thailand, and Vietnam [3]. Group 4: Strategic Benefits - This collaboration is expected to create long-term growth opportunities for the company and sustainable value for shareholders by expanding its international presence and leveraging local resources for efficient market entry [4]. - The partnership enhances the company's brand authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions and broadening its market in digital health management [4].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing mental health needs in the region [1][4]. Group 1: Partnership Details - The collaboration includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - Silk Road will lead the application for national innovation pilot projects, facilitating the company's engagement with Malaysian authorities [3]. - The partnership will also focus on clinical pilot projects in hospitals, with Silk Road identifying target hospitals and the company adapting products for local use [3]. - Both parties will work together to expand market presence in Malaysia and other Southeast Asian countries, including Indonesia, Thailand, and Vietnam [3]. Group 2: Market Context and Opportunities - Malaysia is facing challenges related to an aging population and increasing mental health demands, with 3.8 million people aged over 60 in 2023 and a significant shortage of mental health resources [1]. - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first approved digital therapy for cognitive impairment, already included in the reimbursement catalog of 30 provinces in China [1]. - The partnership is expected to enhance the company's international presence and brand influence, leveraging Silk Road's extensive local resources and networks in Malaysia to accelerate market entry and improve commercial conversion efficiency [4].

Group 1 - The company announced the completion of a placement of 92 million shares at a price of HKD 5.6 per share on January 27, 2026, with at least six independent third-party subscribers [1] - Following the completion of the placement, the company will issue 92 million shares under a subscription agreement at the same price of HKD 5.6 per share on February 5, 2026 [1] - The estimated net proceeds from the placement and subscription, after deducting all related expenses, are approximately HKD 501 million [1]

于配售事项及先旧后新认购事项完成后，经扣除所有相关费用、成本及开支(包括但不限于法律开支及 支出)的所得款项净额总额估计约为 5.01亿港元。 由于完成先旧后新认购事项的所有条件已达成，本公司于2026年2月5日根据配售及认购协议的条款及条 件按每股先旧后新认购股份5.6港元向卖方配发及发行9200万股先旧后新认购股份。 智通财经APP讯，脑动极光-B(06681)发布公告，配售事项已根据配售及认购协议的条款及条件于2026年 1月27日完成，配售代理按尽力基准成功按配售价每股配售股份5.6港元向不少于六名承配人配售合共 9200万股配售股份。据董事经作出一切合理查询后所深知、尽悉及确信，承配人及其最终实益拥有人均 为独立第三方。 ...